PARGY-LAD
PARGY-LAD.svg
Clinical data
Other namesPARGY-LAD, 6-propynyl- 6-nor- Lysergic acid diethylamide, (6aR,9R)- N,N- diethyl- 7-propynyl- 4,6,6a,7,8,9- hexahydroindolo- [4,3-fg] quinoline- 9- carboxamide
Routes of
administration
Oral
Legal status
Legal status
Identifiers
  • (8β)-N,N-Diethyl-6-prop-2-yn-1-yl-9,10-didehydroergoline- 8- carboxamide
PubChem CID
ChemSpider
Chemical and physical data
FormulaC22H25N3O
Molar mass347.462 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)[C@@H]2C=C1c3cccc4[nH]cc(C[C@H]1N(C2)CC#C)c34
  • InChI=1S/C22H25N3O/c1-4-10-25-14-16(22(26)24(5-2)6-3)11-18-17-8-7-9-19-21(17)15(13-23-19)12-20(18)25/h1,7-9,11,13,16,20,23H,5-6,10,12,14H2,2-3H3/t16-,20-/m1/s1 checkY
  • Key:BPJKJUFQSNRQCR-OXQOHEQNSA-N checkY
  (verify)

PARGY-LAD is an analogue of LSD. It is described by Alexander Shulgin in the book TiHKAL. PARGY-LAD is a hallucinogenic drug similar to LSD, but is considerably less potent than LSD with a dose of 160 micrograms producing only mild effects, and 500 micrograms required for full activity.[2]

References

  1. ^ "Arrêté du 20 mai 2021 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants". www.legifrance.gouv.fr (in French). 20 May 2021.
  2. ^ "#51. PRO-LAD".Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.